InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Inhibrx Biosciences, Inc.

INBX Clue Score25
United States Fiscal year ends December CIK 0002007919
$95.01 +2.43% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $95.01 +171.46% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 29 May 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue1.8Operating income−219.2Net income−241.4EPS, diluted−20.48Fiscal year 2024Revenue0.2 −88.9%Operating income−331.4Net income1,687.6EPS, diluted112.62Fiscal year 2025Revenue1.3 +550.0%Operating income−135.0Net income−140.1 −108.3%EPS, diluted−9.04 −108.0%
FY2023FY2024FY2025
Revenue 1.8 0.2 1.3
Growth −88.9% +550.0%
Operating income −219.2 −331.4 −135.0
Net income −241.4 1,687.6 −140.1
Growth −108.3%
EPS, diluted −20.48 112.62 −9.04
Growth −108.0%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−12,178.9%Net margin−13,408.9%Free cash flow margin−10,994.6%Fiscal year 2024Operating margin−165,724.0%Net margin843,786.0%Free cash flow margin−98,503.0%Fiscal year 2025Operating margin−10,386.5%Net margin−10,773.5%Free cash flow margin−9,986.5%
FY2023FY2024FY2025
Operating margin −12,178.9% −165,724.0% −10,386.5%
Net margin −13,408.9% 843,786.0% −10,773.5%
Free cash flow margin −10,994.6% −98,503.0% −9,986.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−193.3Capital expenditure−4.6Free cash flow−197.9Fiscal year 2024Operating cash flow−194.4Capital expenditure−2.6Free cash flow−197.0Fiscal year 2025Operating cash flow−129.8Capital expenditure−0.0Free cash flow−129.8
FY2023FY2024FY2025
Operating cash flow −193.3 −194.4 −129.8
Capital expenditure −4.6 −2.6 −0.0
Free cash flow −197.9 −197.0 −129.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Cash277.9Total debt207.0Net cash (debt)71.0Shareholders’ equity43.5Debt to equity4.76Fiscal year 2024Cash152.6Total debt0.0Net cash (debt)152.6Shareholders’ equity133.6Debt to equity0.00Fiscal year 2025Cash124.2Total debt100.6Net cash (debt)23.7Shareholders’ equity8.0Debt to equity12.58
FY2023FY2024FY2025
Cash 277.9 152.6 124.2
Total debt 207.0 0.0 100.6
Net cash (debt) 71.0 152.6 23.7
Shareholders’ equity 43.5 133.6 8.0
Debt to equity 4.76 0.00 12.58

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
1.8 0.2 1.3
Growth −88.9% +550.0%
191.6 203.7 113.0
29.4 127.9 23.3
−219.2 −331.4 −135.0
Growth
−239.7 1,687.6 −140.1
0.0 0.0 0.0
−241.4 1,687.6 −140.1
Growth −108.3%
Per share
−20.48 114.01 −9.04
−20.48 112.62 −9.04
Growth −108.0%
11.8 14.8 15.5
11.8 15.0 15.5
Growth +27.2% +3.4%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 3 years on file.